You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    SBC: NEUROP, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NCI

    DESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Mucins in the Diagnosis and Prognosis of Pancreatic Diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Minimal piggyBac vectors for chromatin integration

    SBC: EXSCIEN CORPORATION            Topic: NIGMS

    In this grant, we describe novel transposon piggyBac vectors engineered to deliver transgenes as efficiently as currently available piggyBac systems, but with significantly less helper DNA co-delivered into the host genome. To generate these plasmids, we first identified an important and previously unreported aspect of transposon biology, that the full-length terminal domains required for successf ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage

    SBC: EXSCIEN CORPORATION            Topic: NINDS

    DESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Robotic whole organism HTS platform for drug discovery and development

    SBC: Luminomics Inc.            Topic: NCATS

    DESCRIPTION (provided by applicant): Our goal is to create a compact, affordable, fully automated, screening system for large-scale drug 2 testing in living small animal disease models (e.g., worms, flies, and fish). Modern drug discovery is 3 driven by high-throughput screening (HTS) systems that have the capacity to evaluate large chemical 4 compound 'libraries'. The majority of hits ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. New Functionally-Graded Biohybrid Vascular Graft

    SBC: Vivo Biosciences Inc            Topic: NCATS

    DESCRIPTION (provided by applicant): In this Phase I STTR proposal, our RandD goal is the development and evaluation of a novel functionally-graded biohybrid vascular graft for small diameter (lt6 mm) coronary bypass applications. Tissue engineered vascular constructs developed to date have mostly utilized synthetic and animal- derived biomaterials and require pre-seeding of host cells before impl ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins

    SBC: LI-COR, Inc.            Topic: 100

    DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government